Compare Apartment Investment and Management Co (AIV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apartment Investment and Management Co vs Sana Biotechnology Inc — how do they compare? Apartment Investment and Management Co trades at $2.89 (market cap $422.94M), while Sana Biotechnology Inc trades at $3.98 (market cap $1.15B). The key difference: Sana Biotechnology Inc is far larger — about 2.7× Apartment Investment and Management Co's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | SANA | |
|---|---|---|
Market Cap | $422.94M | $1.15B |
Sector | Real Estate | Health |
52-Week High | $8.76 | $5.92 |
52-Week Low | $2.87 | $2.68 |
Enterprise Value | $669.06M | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
SANA Biotechnology trades at $3.97, down 1.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative ROE and ROA, while analyst consensus is strongly bullish with 82% buy ratings. Recent news highlights clinical data presentations and a $69 million share sale via an ATM facility in May 2026.
Outlook remains speculative with high investor optimism driven by clinical progress, but significant financial losses and cash burn pose risks. Upside depends on successful drug development, while downside risks include funding needs and trial setbacks. The stock offers high-risk, high-reward potential for biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
